Atorvastatin/aspirin/ramipril - Ferrer Internacional

Drug Profile

Atorvastatin/aspirin/ramipril - Ferrer Internacional

Alternative Names: Aspirin/ramipril/atorvastatin; Atorvastatin/acetylsalicylic acid/ramipril; Atorvastatin/ASA/ramipril; Ramipril/atorvastatin/aspirin; Trinomia

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferrer
  • Class Heterocyclic bicyclo compounds; Naphthalenes; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiovascular disorders
  • Phase II Hypertension

Most Recent Events

  • 06 Feb 2018 Phase-III clinical trials in Cardiovascular disorders (In adults; In elderly) in Spain (PO) (EudraCT2017-002343-14)
  • 20 Feb 2017 Phase-III VULCANO clinical trials in Cardiovascular disorders (Prevention; In adults; In elderly) in Spain (PO) (EudraCT2016-004015-13)
  • 11 Mar 2016 Phase-III SECURE trial in Cardiovascular disorders (Prevention; In Elderly) in Czech Republic (PO) (EudraCT2015-002868-17)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top